The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.
J. Mikhael
Research Funding - Celgene; Genzyme; Novartis; Sanofi
V. Rajkumar
No relevant relationships to disclose
V. Roy
No relevant relationships to disclose
S. R. Hayman
No relevant relationships to disclose
R. Fonseca
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genzyme; Lilly; Medtronic; Otsuka
Research Funding - Cylene; Onyx
K. Detweiler Short
No relevant relationships to disclose
B. LaPlant
No relevant relationships to disclose
K. M. Laumann
No relevant relationships to disclose
A. Dispenzieri
Honoraria - Binding Site
Research Funding - Celgene
M. Lacy
Research Funding - Celgene